findmyKOL
Clinical trialNCT02568449CompletedPhase 2Interventional

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

SponsorBarbara Ann Karmanos Cancer InstituteEnrollment20Recurrent Pleural Malignant MesotheliomaStage IV Pleural Mesothelioma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, United States

  • Wayne State University/karmanos Cancer Institute

    Detroit, Michigan, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nintedanib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Mar 2016
Primary completion
1 Jan 2017
Completion
26 Jun 2018
Last update posted
9 Dec 2021
Registered enrollment
20
Registry id
NCT02568449
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.